Does the carbon monoxide transfer coefficient (KCO) correct for a submaximal inspiratory effort?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does KCO Correct for Submaximal Inspiration?

No, KCO (the carbon monoxide transfer coefficient) does not truly "correct" for submaximal inspiration—it is fundamentally a rate constant that increases when alveolar volume (VA) is reduced, regardless of the mechanism causing that reduction. 1, 2

Understanding the Physiology

KCO is essentially the rate constant for alveolar CO uptake (Krogh's kco), not a correction factor. The relationship between DLCO and lung volume is not linear, so DLCO/VA (KCO) does not provide an appropriate way to normalize DLCO for lung volume 3. When you divide DLCO by VA, you're simply expressing the rate constant in different units—you're not "correcting" anything in the true sense.

What Happens with Submaximal Inspiration

In healthy subjects, when VA is reduced by submaximal inflation:

  • KCO increases predictably 1
  • This increase follows the mathematical relationship: KCO/KCOtlc = 0.42 + 0.58/(VA/VAtlc) 4
  • The increase occurs because the same amount of functioning alveolar-capillary membrane is now distributed across a smaller measured volume

Critical Clinical Pitfall

The major problem is that the same DLCO can occur with various combinations of KCO and VA, each suggesting completely different pathologies 2. For example:

  • Extrapulmonary restriction (submaximal inspiration from chest wall/respiratory muscle weakness): Low VA, elevated KCO (>120% predicted) 5, 2
  • Interstitial lung disease: Low VA, low or normal KCO (40-120% predicted depending on pathology) 2
  • Emphysema: Low VA from gas maldistribution, variable KCO depending on severity 2

The Evidence on Respiratory Muscle Weakness

Studies specifically examining submaximal inspiration due to respiratory muscle weakness demonstrate the limitations:

  • Patients with isolated diaphragm or inspiratory muscle weakness show reduced TLC and VA with increased KCO (114-130% predicted) 5
  • However, the increase in KCO with inspiratory muscle weakness was often less than expected compared to normal subjects at similar VA reductions 5
  • This suggests that even in "pure" submaximal inspiration, KCO doesn't perfectly account for the volume reduction

Proper Interpretation Strategy

The guideline recommendation is clear: examine KCO and VA separately, as this provides information on disease pathophysiology that cannot be obtained from their product (DLCO) 3.

When you see reduced VA with elevated KCO:

  • Consider extrapulmonary restriction (chest wall, pleural disease, respiratory muscle weakness)
  • Verify with TLC measurement by body plethysmography
  • A low VA from single-breath test should not be interpreted as demonstrating restriction 3

When you see reduced VA with reduced KCO:

  • Consider parenchymal lung disease (emphysema, interstitial disease)
  • The pattern helps differentiate underlying pathology

Bottom Line

KCO mathematically changes when VA changes, but this is a physiological relationship, not a correction. Calling it a "correction" is physiologically incorrect and clinically misleading 2. Instead, interpret KCO and VA as separate, complementary measurements that together reveal the underlying pathophysiology.

Related Questions

What are the possible causes of a large difference between Transfer Lung Capacity for Carbon Monoxide (TLCO) and Carbon Monoxide Transfer Coefficient (KCO)?
What does a low DLCO (Diffusing Capacity of the Lung for Carbon Monoxide)/VA (Alveolar Volume) ratio indicate and how is it managed?
Given a patient with DLCO (uncorrected) 72% predicted, DLCO (corrected) 67% predicted, DL/VA 64% predicted, alveolar volume (VA) 103% predicted, slow vital capacity (SVC) 94% predicted, inspiratory capacity (IC) 70% predicted, and total lung capacity (TLC) 127% predicted, what is the most likely diagnosis and appropriate treatment plan?
What is the interpretation of pulmonary function test results with DLCO uncorrected 70% predicted, DLCO corrected 67% predicted, alveolar volume (VA) 92% predicted, and KCO 72% predicted, and what further evaluation is recommended?
Why should we measure KCO (transfer coefficient for carbon monoxide) in addition to DLCO (diffusing capacity of the lung for carbon monoxide) rather than relying on DLCO alone?
Is it safe for a healthy adult with normal renal function and no cardiac conduction abnormalities to use oral magnesium supplementation for insomnia or muscle cramps?
In an adult (male or post‑menopausal female) with low ferritin and no obvious menstrual blood loss, should fecal calprotectin be included in the diagnostic workup?
How should a combination cream containing fusidic acid 2% and betamethasone valerate 0.1% be used for severe stasis dermatitis?
In an adult inpatient with normal liver and kidney function, how quickly can duloxetine be increased?
How should a suspected case of Ménière's disease be evaluated?
Could my generalized muscle weakness, shaking on waking, chest cramping, normal complete blood count and comprehensive metabolic panel, and a high‑titer antinuclear antibody (ANA) with anti‑RNP antibodies indicate a life‑threatening condition?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.